blood droplet
Use of liquid biopsy dPCR assays for monitoring resistance and response

Digital PCR (dPCR) is an established method for the fast and reliable identification of significant cancer-related mutations. For liquid biopsy analysis, dPCR assays are a precise, cost-effective, and rapid method for monitoring response and resistance to treatment by testing for relevant cancer-driver and therapy-resistant mutations.

The TaqMan dPCR Liquid Biopsy assays detect and quantify the most common cancer-related mutations (e.g., EGFR, BRAF, KRAS, PIK3CA, JAK2), as well as therapy-resistant mutations (e.g., EGFRT790M). They have been verified and are guaranteed* to perform on the QuantStudio 3D Digital PCR System and other dPCR and droplet digital PCR (ddPCR) instruments, including the Bio-Rad QX-100™ and QX-200™ systems and the Combinati™ Absolute Q™ dPCR System.** To learn more about the Combinati Absolute Q dPCR System, visit www.combinati.com.

White Paper: Minimally invasive, sensitive detection of rare cancer mutations using digital PCR

Liquid biopsies are increasingly being used in the detection of rare mutations for monitoring disease progression and resistance to therapy. In this white paper, learn more about the use of digital PCR as a sensitive technology for the identification of cancer driver and resistance mutations.

Download whitepaper

White Paper: Minimally invasive, sensitive detection of rare cancer mutations using digital PCR

Key features of the TaqMan Liquid Biopsy dPCR Assays

  • Optimized dPCR performance—wet lab–verified TaqMan assays targeting over 100 common cancer mutations including NSCLC, breast cancer, and CRC markers including:
  • o EGFR p.T790M
  • o EGFR p.L858R
  • o BRAF p.V600E
  • o KRAS p.G12D
  • o TERT p.C228T
  • o TERT p.C250T
  • Highly sensitive—detect and quantify rare mutant prevalence to ≤0.1%
  • Cost-effective, single-tube assay—single-tube format includes both wild type and mutant alleles
  • Streamlined analysis—enhanced bioinformatics tools for better quantification of rare mutations
  • Guaranteed performance—backed by the TaqMan performance guarantee


Order TaqMan dPCR Liquid Biopsy Assays

Assay Search Tool:

QuantStudio 3D Digital PCR System

Absolute quantification, using sealed-chip technology, for a reliable method and precise, sensitive data.

Request a quote     Product bulletin     Product overview

Analysis Suite cloud-based software

Additional liquid biopsy solutions

Targeted next-generation sequencing (NGS) assays

Exosome isolation

Rare mutation detection assays

Resources
Support

For Research Use Only. Not for use in diagnostic procedures.

* Terms and conditions apply. For complete details, go to www.thermofisher.com/taqmanguarantee.

** Bio-Rad and Bio-Rad QX100 and QX200 Droplet Digital PCR Systems are trademarks of Bio-Rad Laboratories, Inc., which is not affiliated with Thermo Fisher Scientific. These statements have not been reviewed or endorsed by Bio-Rad. Combinati and Absolute Q are trademarks of Combinati Inc. TaqMan is a registered trademark of Roche Molecular Systems, Inc., used under license.